Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jan 29:10:14.
doi: 10.3389/fendo.2019.00014. eCollection 2019.

History of the Obesogen Field: Looking Back to Look Forward

Affiliations
Review

History of the Obesogen Field: Looking Back to Look Forward

Jerrold J Heindel. Front Endocrinol (Lausanne). .

Abstract

The Obesogen field developed from two separate scientific research areas, endocrine disruptors and the Developmental Origins of Health and Disease (DOHaD). Endocrine Disrupting Chemicals (EDCs) are exogenous chemicals or mixtures of chemicals that interfere with the action of hormones. Exposure to EDCs during early development (DOHaD) has been shown to increase susceptibility to a variety of diseases including infertility, asthma, breast and prostate cancer, early puberty, susceptibility to infections, heart disease, autoimmune disease, and attention deficit hyperactivity disorder/learning disability. The effects of EDCs on obesity and fat cell development first gained attention around the turn of the twenty-first century. In 2002 Dr. Paula Baillie-Hamilton wrote the first review article focusing on environmental chemicals and obesity. She suggested that the obesity epidemic correlated with the increased production of chemicals after World War II. Baillie-Hamilton identified studies showing that exposures to a variety of chemicals led to weight gain. Shortly after that a commentary on an article showing that nonylphenol would increase fat cell differentiation in vitro noted the Baillie-Hamilton article and made the point that perhaps obesity was due in part to exposure to EDCs. In 2006 the field of DOHaD/EDCs and obesity made a giant leap forward when Dr. Bruce Blumberg published a paper showing that tributyltin could lead to weight gain in mice and coined the term obesogen for a chemical that caused weight gain and lead to obesity. In 2011, the NIEHS developed the first funding initiative focused on obesogens. In the following years there have been several workshops focused on obesogens. This paper describes these early days that lead to the obesogen hypotheses and the growth of the field for a decade, leading to its prominence today, and provides some insight into where the field is moving.

Keywords: developmental origins of disease; endocrine disruptor; metabolism disruptor; obesity; obesogen.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Timeline of obesogen field.

References

    1. Serretti A, Mandelli L. Antidepressants and body weight: a comprehensive review and meta-analysis. J Clin Psychiatry (2010) 71:1259–72. 10.4088/JCP.09r05346blu - DOI - PubMed
    1. Zhang J, Liu X, Xie XB, Cheng XC, Wang RL. Multitargeted bioactive ligands for PPARs discovered in the last decade. Chem Biol Drug Des. (2016) 88:635–63. 10.1111/cbdd.12806 - DOI - PubMed
    1. Roman-Ramos R, Almanza-Perez JC, Garcia-Macedo R, Blancas-Flores G, Fortis-Barrera A, Alarcon-Aguilar FJ. Monosodium glutamate neonatal intoxication associated with obesity in adult stage is characterized by chronic inflammation and increased mRNA expression of peroxisome proliferator-activated receptors in mice. Basic Clin Pharmacol Toxicol. (2011) 108:406–13. 10.1111/j.1742-7843.2011.00671.x - DOI - PubMed
    1. Schug TT, Johnson AF, Birnbaum LS, Colborn T, Guillette LJ, Heindel JJ. Minireview: endocrine disruptors: past lessons and future directions. Mol Endocrinol. (2016) 30:833–47. 10.1210/me.2016-1096 - DOI - PMC - PubMed
    1. Gore AC, Chappell VA, Fenton SE, Flaws JA, Nadal A, Zoeller RT. EDC-2: the endocrine society's second scientific statement on endocrine-disrupting chemicals. Endocr Rev. (2015) 36:E1–e150. 10.1210/er.2015-1010 - DOI - PMC - PubMed

LinkOut - more resources